Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
19.15
-0.41 (-2.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Hutchmed China Ltd ADR
< Previous
1
2
3
Next >
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
April 26, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
April 05, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
April 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
March 27, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
February 28, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
February 06, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
February 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Final Results
February 01, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
January 29, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
January 10, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms
December 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
November 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
November 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
November 08, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
November 01, 2023
Virtual Investor Conference on November 8th and 9th, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
October 16, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
September 29, 2023
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer
September 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
September 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
August 28, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
August 20, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Reports 2023 Interim Results and Provides Business Updates
July 31, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study
July 19, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Changes to Board of Directors and Technical Committee
July 13, 2023
Ms Ling Yang to replace Mr Lefei Sun as Non-executive Director; Professor Solange Peters appointed as Special Advisor to the Technical Committee
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China
July 09, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED to Announce 2023 Half-Year Financial Results
June 26, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings
June 09, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.